Printer Friendly

SMITHKLINE BEECHAM ANNOUNCES 1992 RESULTS: EARNINGS INCREASE 14 PERCENT; SALES UP 11 PERCENT

 PHILADELPHIA, Feb. 23 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) announced today that sales rose 11 percent for the year ending Dec. 31, 1992. Pre-tax profit was up 11 percent and earnings per share increased 14 percent to 47.8 cents/27.3 pence.
 For the fourth quarter, sales were up 18 percent, pre-tax profit increased 16 percent and earnings per share rose 19 percent to 13.3 cents/7.6 pence.
 At comparable rates of exchange, sales for the year rose 10 percent, pre-tax profits 15 percent, and earnings per share 17 percent.
 Commenting on the results, Robert P. Bauman, SmithKline Beecham chief executive, said: "1992 was a very successful year.
 "The key to SmithKline Beecham's success is our ability to exploit globally our marketing and selling strengths and to maximize the potential of the growing number of new products emerging from our pipeline.
 "Our basic strategies of building leadership in research and development, being the most effective marketers, the best managed company and the lowest-cost producer are moving forward. We are on the right track for continued growth despite an increasingly challenging worldwide environment."
 The following business sector comparisons are made at comparable exchange rates.
 Pharmaceuticals
 Sales increased 15 percent and operating profit (trading profit) was up 12 percent for the year. Performance was led by U.S. sales, which grew an impressive 16 percent. European performance was highlighted by a 14 percent increase in sales in France, a 12 percent rise in Italy, and 10 percent growth in Spain.
 Pharmaceutical sales registered excellent growth in smaller, developing markets. In Eastern Europe, sales rose 92 percent; in Africa, 29 percent; and, in China, 68 percent.
 New products made a significant contribution to sales in 1992. Sales of SB's four major new products totalled more than $350 million/200 million pounds sterling.
 Seroxat/Paxil is the fastest growing antidepressant in the U.K., Netherlands and Ireland. It was approved in 25 markets in 1992 including, at year's end, the United States.
 Relafen, the arthritis medication, finished its first 10 months in the U.S. market as one of the three top products in its category.
 Kytril, the injectable anti-emetic for patients undergoing cancer therapy, was approved in 12 markets. It had strong performance in Japan, France and Switzerland.
 Havrix, the world's first hepatitis A vaccine, had strong sales on launch in six European markets and Hong Kong.
 Augmentin, the broad spectrum antibiotic, became SB's second $1 billion drug with sales of $1.03 billion/589 million pounds, a 14 percent increase over 1991. Sales growth accelerated in European and Asian markets. U.S. sales increased in a weak market.
 Engerix-B, the genetically engineered hepatitis B vaccine, had an extraordinary year with sales increasing 154 percent. The increase reflected the growing awareness of the importance of hepatitis B vaccination and, to a lesser degree, supply problems of a competitor.
 Sales of Tagamet, the peptic ulcer medicine, topped $1 billion for the seventh straight year.
 Animal Health
 Animal Health finished the year with a good fourth quarter. For the year, sales were up 4 percent and operating profit increased 2 percent despite weak global markets. Excluding the impact of the FDA-mandated withdrawal of nitrofuran products from the U.S. market in the fourth quarter of 1991, sales would have increased 7 percent and operating profit 10 percent.
 The resurgence in the fourth quarter was paced by strong sales of cattle biologicals in the U.S. and strong biological and antibiotic sales in Europe.
 SmithKline Beecham's leadership in animal vaccines was bolstered by the introduction of One Shot, a single-dose vaccine against bovine shipping fever, and Defensor, a three-year rabies vaccine for cats and dogs.
 Consumer Brands
 Consumer Brands had a sales increase of 1 percent. Operating profit was up 10 percent due to a continued drive for efficiencies and as a result of the disposal of several personal care product lines in connection with a strategic repositioning intensifying focus on healthcare.
 Major brands continued to perform well. Sales of Tums increased 23 percent and Oxy increased 6 percent. In health drinks, Ribena sales were up 10 percent, Horlicks rose 5 percent and Lucozade was unchanged from 1991.
 Oral Care products increased 12 percent, led by Germany, where SmithKline Beecham is now the leader in the category, and the U.K., where the company is the leader in toothpastes.
 The Aquafresh line extension to include a toothpaste for sensitive teeth and the acquisition of Corsodyl, a clinically tested gum disease treatment with potential to become a major brand in Europe, enhanced SB's oral care business.
 A key event in 1992 was the partnership in the United States with Marion Merrell Dow, which strengthened the potential for leadership in over-the-counter medicines.
 Also, to bring a more global perspective to the worldwide development of major brands, the business was reorganized with the former regional structure being replaced by a category management system with global product responsibility.
 Clinical Laboratories
 Clinical Laboratories had another record year with sales up 11 percent and operating profit up 16 percent. On a local currency basis, clinical laboratories reached the $1 billion dollar sales milestone in 1992.
 Growth was led by industrial drug testing which increased 46 percent, double the pace of the growing U.S. market.
 New marketing initiatives in 1992 included the National Sports Testing Center in Atlanta, providing substance abuse testing for professional, college and high school athletes.
 The company also established the Clinical Trials Euro Centre at Genval, Belgium, the first laboratory for centralized testing for companies conducting clinical trials in Europe.
 Dividend
 A quarterly dividend of 2.375 pence per A Share equivalent to 4.605 cents per Equity Unit and 23.025 cents per Equity Unit ADR (SBE) has been declared. Payment will be on April 15, 1993, to shareholders of record on March 11, 1993. An exchange rate of $1.4542 to 1 pound has been used, which was the opening exchange rate in London on Feb. 23, 1993.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and clinical laboratory testing services.
 SMITHKLINE BEECHAM
 Consolidated Profit and Loss Account
 Year ended Dec. 31, 1992
 (Unaudited)
 1992 1991 Increase 1992
 Pounds Pounds percent Dollars
 million million million(A)
 Sales (B) 5,219 4,685 11 9,133
 Cost of goods sold (1,763) (1,647) (3,085)
 Gross profit 3,456 3,038 14 6,048
 Selling, general and
 administrative expenses (1,837) (1,549) (3,215)
 Research & development
 expenditure (478) (432) (836)
 Trading profit (B) 1,141 1,057 8 1,997
 Share of profits of associated
 undertakings 5 4 8
 Interest (31) (59) (54)
 Profit on ordinary activities
 before taxation 1,115 1,002 11 1,951
 Tax on profit on ordinary
 activities (C) (360) (329) (630)
 Profit on ordinary activities
 after taxation 755 673 12 1,321
 Minority interests (11) (11) (19)
 Auction Rate Preference Share
 dividends (16) (24) (28)
 Profit attributable to
 shareholders 728 638 14 1,274
 Dividends payable (D) (267) (238) (467)
 Profit retained 461 400 807
 Earnings per
 Share/Equity Unit (E) 27.3p 24.0p 14 47.8c
 Earnings per
 Equity Unit ADR (E) 136.5p 120.0p 14 238.9c
 (A) The translation of pounds sterling into U.S. dollars has been made at $1.75 to 1 pound (the average rate for the year ended Dec. 31, 1992) solely for the convenience of the reader.
 SMITHKLINE BEECHAM
 Summary Consolidated Balance Sheet
 As of Dec. 31, 1992 (unaudited)
 Dec. 31 Dec. 31 Dec. 31
 1992 1991 1992
 Pounds Pounds Dollars
 million million million(A)
 Fixed Assets:
 Tangible assets 1,846 1,551 2,787
 Investments 64 44 97
 Total 1,910 1,595 2,884
 Current assets:
 Stocks 582 526 879
 Debtors - due within one year 1,366 1,100 2,063
 - due after more than one year 105 104 158
 Cash and investments 1,136 782 1,715
 Total 3,189 2,512 4,815
 Creditors - within one year
 Loans and overdrafts (1,309) (1,032) (1,977)
 Other (1,640) (1,356) (2,476)
 Total (2,949) (2,388) (4,453)
 Net current assets 240 124 362
 Total assets less current liabilities 2,150 1,719 3,246
 Creditors - more than one year
 Loans (219) (252) (331)
 Other (55) (29) (83)
 Provisions for
 liabilities and charges (240) (234) (362)
 Total (514) (515) (776)
 NET ASSETS 1,636 1,204 2,470
 Capital and reserves:
 Called up share capital 356 351 538
 Reserves 724 392 1,093
 SB Shareholders' Equity 1,080 743 1,631
 Auction Rate Preference
 Shares of subsidiary 530 428 800
 Minority interests 26 33 39
 TOTAL SHAREHOLDERS' FUNDS 1,636 1,204 2,470


(A) The translation of pounds sterling into U.S. dollars has been made at $1.51 to 1 pound (the rate applicable at Dec. 31, 1992) solely for the convenience of the reader.
 SMITHKLINE BEECHAM
 Cash Flow Statement
 Year ended December 31, 1992 (unaudited)
 Dec. 31 Dec. 31 Dec. 31
 1992 1991 1992
 Pounds Pounds Dollars
 million million million(A)
 Net cash inflow from
 trading activities 1,294 1,122 2,265
 Restructuring costs paid (120) (177) (210)
 Returns on investments
 and servicing of finance:
 Net interest paid (34) (59) (59)
 Dividends paid (269) (261) (471)
 Net cash outflow from returns on
 investments and servicing of finance (303) (320) (530)
 Tax paid (227) (216) (397)
 Investing activities:
 Purchase less sale of
 tangible fixed assets (275) (244) (481)
 Purchase of businesses (150) (22) (263)
 Sale of businesses 87 57 152
 Purchase of trade investments (13) (11) (23)
 Net cash outflow from
 investing activities (351) (220) (615)
 Net cash inflow before financing 293 189 513
 Financing:
 Issue of share capital 18 21 32
 Movements in longer term financing (54) (143) (95)
 Net cash outflow from financing (36) (122) (63)
 Increase in cash and cash equivalents 257 67 450
 Total net borrowings:
 At beginning of year (502) (676) (879)
 Exchange restatement (201) (36) (352)
 Net cash inflow 293 189 513
 Issue of share capital 18 21 32
 At end of year (392) (502) (686)


(A) The translation of pounds sterling into U.S. dollars has been made at $1.75 to 1 pound (the average rate for the year ended Dec. 31, 1992) solely for the convenience of the reader.
 SMITHKLINE BEECHAM
 Notes
 1. BASIS OF PREPARATION
 The unaudited results for the year ended Dec. 31, 1992, have been prepared in accordance with U.K. generally accepted accounting principles. The accounting policies applied are those set out in the Annual Report and Accounts for the year ended Dec. 31, 1992.
 (B) Segment Information:
 1992 1991 Increase/ 1992
 Pounds Pounds (Decrease) Dollars
 million million percent million(A)
 SALES BY BUSINESS SECTOR
 Pharmaceuticals 2,889 2,470 17 5,056
 Animal Health 337 318 6 590
 Consumer Brands 1,384 1,358 2 2,422
 Clinical Laboratories 609 539 13 1,065
 TOTAL 5,219 4,685 11 9,133
 TRADING PROFIT BY BUSINESS SECTOR
 Pharmaceuticals 758 694 9 1,327
 Animal Health 62 63 (2) 108
 Consumer Brands 244 232 5 427
 Clinical Laboratories 77 68 14 135
 TOTAL 1,141 1,057 8 1,997
 SALES BY LOCATION OF CUSTOMER
 United Kingdom 508 504 1 889
 United States of America 2,361 2,078 14 4,132
 Continental Europe 1,398 1,273 10 2,446
 Rest of the World 952 830 15 1,666
 TOTAL 5,219 4,685 11 9,133
 (A)The translation of pounds sterling into U.S. dollars has been made at $1.75 to 1 pound (the average rate for the year ended Dec. 31, 1992) solely for the convenience of the reader.
 (C) TAXATION
 The tax on profit on ordinary activities comprises:
 1992 1991 1992
 m pound m pound US$m(A)
 United Kingdom taxation 68 32 119
 Overseas taxation (including associated
 undertakings) 292 297 511
 360 329 630
 (D) DIVIDENDS
 To the 'A' Shareholders of the Company
 Pence per
 Share m pound
 Interim dividends
 First - paid 2.075 28
 Second - paid 2.075 28
 Third - paid 2.075 29
 Fourth - payable 2.375 32
 8.600 117
 To the holders of Equity Units through SmithKline Beecham Corporation
 Cents per
 Equity Unit m pound
 Interim dividends
 First - paid 4.877 36
 Second - paid 5.279 36
 Third - paid 4.503 36
 Fourth - payable 4.605 42
 19.264 150
 (A) The translation of pounds sterling into U.S. dollars has been made at $1.75 to 1 pound (the average rate for the year ended Dec. 31, 1992) solely for the convenience of the reader.


SmithKline Beecham Notes
 Dividends paid by SmithKline Beecham plc on the 'A' Shares are paid net and carry a tax credit for United Kingdom purposes, currently equal to one third of the cash dividend. Dividends on the Equity Units are paid gross by SmithKline Beecham Corporation in the United States. The gross equivalent paid by SmithKline Beecham plc is equal to the amount paid by SmithKline Beecham Corporation. The fourth interim dividend will be paid to holders of record on April 15, 1993.
 (E) EARNINGS PER SHARE 1992 1991 1992 (A)
 Profit attributable to shareholders 728m 638m $1,274m
 Average number of A and B Shares 2,666m 2,656m 2,666m
 Earnings per Share/Equity Unit 27.3p 24.0p 47.8c
 Earnings per Equity Unit ADR 136.5p 120.0p 238.9c
 Earnings per share have been computed to take into account the 2:1 split in the A shares and the 10:1 split in the Equity Units, which occurred on July 13, 1992. On the New York Stock Exchange five new Equity Units were combined to create the Equity Unit ADR. The 1991 comparatives have been restated.
 (F) ANNUAL REPORT
 The Annual Report and Accounts will be mailed to shareholders on March 26, 1993.
 (G) SUMMARY FINANCIAL INFORMATION
 The financial information for the year ended Dec. 31, 1991, has been extracted from the Statutory Accounts for that year which have been delivered to the Registrar of Companies. The Auditors' Report on these Accounts was unqualified and did not contain a statement under Section 237 of the Companies Act 1985. Statutory Accounts for the year ended Dec. 31, 1992, will be delivered to the Registrar of Companies following the Annual General Meeting on April 26, 1993.
 (A) The translation of pounds sterling into U.S. dollars has been made at $1.75 to 1 pound (the average rate for the year ended Dec. 31, 1992) solely for the convenience of the reader.
 /delval/
 -0- 2/23/93
 /CONTACT: Jeremy Heymsfeld, 215-751-5166, or Richard Williams (financial), 215-751-7002, both of SmithKline Beecham/
 (SBH)


CO: SmithKline Beecham ST: Pennsylvania IN: MTC SU: ERN

MP-SF -- PH001 -- 9235 02/23/93 08:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 23, 1993
Words:2465
Previous Article:EVERGREEN ENTERPRISES' DIVIDEND REINVESTMENT PLAN PORTFOLIO TRACKER VERSION 2 TO BE RELEASED APRIL 1993
Next Article:CHARTER GOLF ANNOUNCES RECORD FISCAL 1993 FIRST QUARTER OPERATING RESULTS; SALES INCREASE 71 PERCENT, NET INCOME UP 119 PERCENT
Topics:


Related Articles
SMITHKLINE BEECHAM SALES UP 9 PERCENT, EARNINGS PER SHARE UP 12 PERCENT IN SECOND QUARTER 1992
SMITHKLINE BEECHAM THIRD QUARTER 1992 SALES UP 9 PERCENT; EARNINGS PER SHARE INCREASE 13 PERCENT
SMITHKLINE BEECHAM ANNOUNCES FIRST QUARTER 1993 RESULTS: EARNINGS INCREASE 14 PERCENT; SALES UP 26 PERCENT
SMITHKLINE BEECHAM ANNOUNCES SECOND QUARTER 1993 RESULTS EARNINGS INCREASE 20 PERCENT; PRE-TAX PROFIT 18 PERCENT
SMITHKLINE BEECHAM ANNOUNCES FIRST-QUARTER RESULTS: EARNINGS INCREASE 16 PERCENT; PRE-TAX PROFIT UP 15 PERCENT; DIVIDEND UP 18 PERCENT
SMITHKLINE BEECHAM ANNOUNCES THIRD-QUARTER 1994 RESULTS: SALES INCREASE 8 PERCENT; EARNINGS PER SHARE UP 4 PERCENT; NEW PHARMACEUTICAL PRODUCTS SALES...
KODAK COMPLETES STERLING WINTHROP SALE TO SMITHKLINE BEECHAM
SMITHKLINE BEECHAM ANNOUNCES 1994 RESULTS: SALES FROM CONTINUING OPERATIONS UP 8 PERCENT; OPERATING PROFITS, EXCLUDING ONE-TIME ITEMS, RISE 15...
Smithkline Beecham Reports Strong Growth For 1996, Fueled By Success Of New Products
SmithKline Beecham, Related Entities Ratings Raised by S&P - Standard & Poor's CreditWire -

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters